Why the study?
Does elevated circulating Angiopoietin-2 predict adverse renal outcomes in patients with stages 3-5 CKD?
Does elevated circulating Angiopoietin-2 predict adverse renal outcomes in patients with stages 3-5 CKD?
Elevated circulating Angiopoietin-2 is an independent predictor of adverse renal outcomes, including commencing dialysis and rapid eGFR decline, in patients with stages 3-5 CKD.
Answers are grounded in this paper and cite their sources.
Elevated Angiopoietin-2 may aid prognostication in stages 3-5 CKD; hypothesis-generating for targeted therapies pending confirmatory trials.
BACKGROUND: The pathophysiological mechanisms of renal function progression in chronic kidney disease (CKD) have still not been completely explored. In addition to well-known traditional risk factors, non-traditional risk factors, such as endothelial dysfunction, have gradually attracted physicians' attention. Angiopoietin-2 (Ang-2) impairs endothelial function through preventing angiopoietin-1 from binding to Tie2 receptor. Whether Ang-2 is associated with renal function progression in CKD is unknown. METHODS: This study enrolled 621 patients with stages 3-5 CKD to assess the association of circulating Ang-2 with commencing dialysis, doubling creatinine and rapid decline in renal function (the slope of estimated glomerular filtration rate (eGFR) greater than 5 ml/min per 1.73 m2/y) over follow-up of more than 3 years. RESULTS: Of all patients, 224 patients (36.1%) progressed to commencing dialysis and 165 (26.6%) reached doubling creatinine. 85 subjects (13.9%) had rapid decline in renal function. Ang-2 quartile was divided at 1494.1, 1948.8, and 2593.1 pg/ml. The adjusted HR of composite outcomes, either commencing dialysis or doubling creatinine was 1.53 (95% CI: 1.06-2.23) for subjects of quartile 4 compared with those of quartile 1. The adjusted OR for rapid decline in renal function was 2.96 (95% CI: 1.13-7.76) for subjects of quartile 4 compared with those of quartile 1. The linear mixed-effects model shows a more rapid decrease in eGFR over time in patients with quartile 3 or more of Ang-2 than those with the lowest quartile of Ang-2. CONCLUSIONS: Ang-2 is an independent predictor of adverse renal outcome in CKD. Further study is needed to identify the pathogenic role of Ang-2 in CKD progression.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: